Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15917 ↗At a glance
Vergleichsstudie in Diabetes, Obesity and Metabolism, 2024. Written by Wentong Long and 2 co-authors. Institution: Alberta Diabetes Institute, University of Alberta, 1-005 Li Ka Shing Centre for Health Research Innovation, Edmonton, Alberta, Canada. Major MEDLINE topics: Diabetes Mellitus, Type 2, Acute Coronary Syndrome, Gliclazide, Glyburide. Cited 1 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: CIHR, Canadian Institutes of Health Research.
Topics: Diabetes mellitus
Abstract (original language)
Aim
To examine the likelihood of mortality or rehospitalization following acute coronary syndrome with glyburide versus gliclazide use in adults with type 2 diabetes undergoing cardiac catheterization. Research Design and Methods This retrospective cohort study used clinical data linked with administrative health data from Alberta, Canada between April 2008 and March 2021. Three methods were used to define exposure to glyburide and gliclazide in the year before catheterization. Multivariable logistic regression was used to compare the likelihood of a composite outcome of 1‐year mortality or rehospitalization with use of glyburide versus use of gliclazide.
Results
A total of 11 140 individuals with type 2 diabetes had a cardiac catheterization for acute coronary syndrome. Their mean age was 66 years and 31% were female. In the year before catheterization, 5% used glyburide and 19% used gliclazide. Any glyburide or gliclazide exposure in the year before catheterization was associated with a similar likelihood of all‐cause mortality or rehospitalization (adjusted odds ratio [aOR] 1.14, 95% confidence interval [CI] 0.93–1.41; p = 0.20). However, current glyburide exposure (aOR 1.37, 95% CI 1.06–1.79; p = 0.018) and long exposure to glyburide (aOR 1.37, 95% CI 1.03–1.83; p = 0.030) were associated with a higher likelihood of the composite outcome compared to current and long exposure to gliclazide, respectively.
Conclusions
Current and long exposure to glyburide was associated with a greater likelihood of mortality or rehospitalization following cardiac catheterization for acute coronary syndrome, when compared to similar gliclazide exposure definitions. This study adds further evidence of the need to avoid using glyburide if a sulphonylurea is required for type 2 diabetes management.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Alberta Diabetes Institute, University of Alberta, 1-005 Li Ka Shing Centre for Health Research Innovation, Edmonton, Alberta, Canada.
- Department of Pharmacology, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, Alberta, Canada.
- Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, University of Alberta, Edmonton, Alberta, Canada.
ORCID profiles: Scot H Simpson
Funding
- CIHR
- Canadian Institutes of Health Research
Cite
APA
Long, W., Light, P. E., & Simpson, S. H. (2024). Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15917
Vancouver
Long W, Light PE, Simpson SH. Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15917
BibTeX
@article{Long2024,
author = {Long, Wentong and Light, Peter E and Simpson, Scot H},
title = {Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15917}
}
EUVIMED